Physician profile
Matthew Techy
NPI 1639561590
$1,583.74
in general payments reported to CMS, 2019-2025
14 companies · $855 in 2025
The $855 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2023: $123 · 2024: $487 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418 · Education: $47.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.80 |
| Education | $47.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $471.25 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $213.37 | 2023-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $201.35 | 2024-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $118.44 | 2019 | |
| Emd Serono, INC. | $99.98 | 2024 | Mavenclad |
| Ucb, INC. | $85.66 | 2025 | Briviact, Rystiggo, Zilbrysq |
| Amgen INC. | $76.30 | 2025 | Uplizna |
| Catalyst Pharmaceuticals, INC. | $71.35 | 2024-2025 | |
| Celgene Corporation | $69.02 | 2023-2024 | Zeposia |
| Tanabe Pharma America, INC. | $57.54 | 2024-2025 | Radicava |
| Genentech USA, INC. | $48.16 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Abbvie INC. | $34.30 | 2024 | |
| Acorda Therapeutics, INC | $19.04 | 2024 | Ampyra, Inbrija |
| Biogen, INC. | $17.98 | 2025 | Qalsody, Spinraza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Techy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.